Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCTs031220199
JPRN-jRCTs031220199Active, not recruitingPhase 2

Efficacy and Safety of [11C]MeLeu as a novel PET probe in patients with pancreatic cancer

Yamazaki Kana0 sites20 target enrollmentStarted: July 8, 2022Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Active, not recruiting
Sponsor
Enrollment
20
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 18age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •1.Subjects who are 18 years of age or older at the time of consent acquisition
  • •2.Subjects who have been confirmed to have pancreatic cancer by histopathological or clinical examination
  • •3.Subjects who have performed or are scheduled to perform [18F]FDG PET/CT by insurance within 30 days before or after the date of obtaining [11C]MeLeu PET/CT imaging, if [18F]FDG PET/CT imaging information is to be used
  • •4.Subjects whose Performance Status (ECOG PS) is 0 or 1
  • •5.Subjects who provide written informed consent

Exclusion Criteria

  • •1.Subjects who have severe or progressive complications or subjects who have a history of these complications and are judged by the investigator or co-investigator to be unsuitable for this study
  • •2.Subjects who have obvious abnormalities in physical and laboratory examinations (blood test and urinalysis) after obtaining the informed consent
  • •3.Subjects with drug addiction or alcohol addiction
  • •4.Subjects with mental illness or psychiatric symptoms who are judged to have difficulty in participating in this study
  • •5.Subjects who are unable or restricted from the tests specified in the research plan
  • •6.Subjects who are claustrophobic
  • •7.Subjects who are considered to be inappropriate to participate in this study by the investigator or co-investigator

Investigators

Sponsor
Yamazaki Kana

Similar Trials

Recruiting
Phase 2
Efficacy and safety of MePro in patients with pancreatic cancerPancreatic cancer
JPRN-jRCTs031230331Takahashi Miwako20
Completed
Not Applicable
sefulness of using C-11 methionine PET in patient which suspected gliomaglioma
JPRN-UMIN000022067Hokkaido University Hospital46
Completed
Not Applicable
sefulness of using C-11 methionine PET in patient which suspected gliomaglioma
JPRN-UMIN000022354Osaka University Hospital90
Recruiting
Phase 2
First in patients of a New PET Probe FEDACMalignant tumors(solid tumors)
JPRN-jRCTs031220192Tamura Kentaro30
Completed
Not Applicable
First in Human study of a New PET Probe FEDAC
JPRN-jRCTs031210134Tamura Kentaro10